Paul Webster
Paul Webster has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Marc Michael Baum
Department of Chemistry, Oak Crest Institute of Science, Monrovia, USA
3 shared publications Carrie Arnold
Freelance writer, Richmond, USA
2 shared publicationsJohn Cortez
Oak Crest Institute of Science, 132 W. Chestnut Avenue, Monrovia, California 91016, United States
2 shared publicationsManjula Gunawardana
Department of Chemistry, Oak Crest Institute of Science, Monrovia, USA
2 shared publicationsAbdus A. K. M. Sattar
Department of Surgery & Biomedical Engineering Program, Yale University School of Medicine, New Haven, CT, 06510, U.S.A.
1 shared publication- Alexander O. Gomez
Citrus College
1 shared publication
Latest Publications
- 13 August 2026
- Published by Springer Nature in Nature Medicine
AI decision support is scaling-up fast — can the evidence keep up?
- 13 August 2026
- Published by Springer Nature in Nature Medicine
AI decision support is scaling-up fast — can the evidence keep up?
- 7 May 2024
- Published by Springer Nature in Nature Medicine
- Vol. 30 (6) , 1508-1509
The future of brain–computer interfaces in medicine
- 7 May 2024
- Published by Springer Nature in Nature Medicine
- Vol. 30 (6) , 1508-1509
The future of brain–computer interfaces in medicine
- 12 March 2024
- Published by Springer Nature in Nature Medicine
- Vol. 30 (4) , 914-915
How AI-powered handheld devices are boosting disease diagnostics - from cancer to dermatology
- 12 March 2024
- Published by Springer Nature in Nature Medicine
- Vol. 30 (4) , 914-915
How AI-powered handheld devices are boosting disease diagnostics - from cancer to dermatology
- Open Access
- 11 April 2023
- Published by Pacific University Library - UBIQUITY JOURNALS in International Journal of Undergraduate Research and Creative Activities
- Vol. 15 (1)
A Wild Pseudomonas has appeared: An Exercise in Bacterial Isolation and Identification
- 11 April 2023
- Published by Pacific University Library - UBIQUITY JOURNALS in International Journal of Undergraduate Research and Creative Activities
- Vol. 15 (1)
Open AccessA Wild Pseudomonas has appeared: An Exercise in Bacterial Isolation and Identification
- Open Access
- 27 February 2023
- Published by Springer Nature in Nature Medicine
- Vol. 29 (11) , 2957
Author Correction: 11 clinical trials that will shape medicine in 2023
- 27 February 2023
- Published by Springer Nature in Nature Medicine
- Vol. 29 (11) , 2957
Open AccessAuthor Correction: 11 clinical trials that will shape medicine in 2023
- 23 December 2022
- Published by Springer Nature in Nature Medicine
- Vol. 28 (12) , 2444-2448
11 clinical trials that will shape medicine in 2023
Nature Medicine asks leading researchers to name their top clinical trial for 2023, from cervical and prostate cancer screening to new drugs for Parkinson’s disease and Alzheimer’s disease.
- 23 December 2022
- Published by Springer Nature in Nature Medicine
- Vol. 28 (12) , 2444-2448
11 clinical trials that will shape medicine in 2023
Nature Medicine asks leading researchers to name their top clinical trial for 2023, from cervical and prostate cancer screening to new drugs for Parkinson’s disease and Alzheimer’s disease.
- Open Access
- 23 November 2022
- Published by Springer Nature in Pharmaceutical Research
- Vol. 40 (7) , 1657-1672
Preclinical Considerations for Long-acting Delivery of Tenofovir Alafenamide from Subdermal Implants for HIV Pre-exposure Prophylaxis
Purpose: Long-acting formulations of the potent antiretroviral prodrug tenofovir alafenamide (TAF) hold potential as biomedical HIV prevention modalities. Here, we present a rigorous comparison of three animal models, C57BL/6 J mice, beagle dogs, and merino sheep for evaluating TAF implant pharmacokinetics (PKs). Methods: Implants delivering TAF over a wide range of controlled release rates were tested in vitro and in mice and dogs. Our existing PK model, supported by an intravenous (IV) dosing dog study, was adapted to analyze mechanistic aspects underlying implant TAF delivery. Results: TAF in vitro release in the 0.13 to 9.8 mg d−1 range with zero order kinetics were attained. Implants with equivalent fabrication parameters released TAF in mice and sheep at rates that were not statistically different, but were 3 times higher in dogs. When two implants were placed in the same subcutaneous pocket, a two-week creep to Cmax was observed in dogs for systemic drug and metabolite concentrations, but not in mice. Co-modeling IV and TAF implant PK data in dogs led to an apparent TAF bioavailability of 9.6 in the single implant groups (compared to the IV group), but only 1.5 when two implants were placed in the same subcutaneous pocket. Conclusions: Based on the current results, we recommend using mice and sheep, with macaques as a complementary species, for preclinical TAF implant evaluation with the caveat that our observations may be specific to the implant technology used here. Our report provides fundamental, translatable insights into multispecies TAF delivery via long-acting implants.
- 23 November 2022
- Published by Springer Nature in Pharmaceutical Research
- Vol. 40 (7) , 1657-1672
Open AccessPreclinical Considerations for Long-acting Delivery of Tenofovir Alafenamide from Subdermal Implants for HIV Pre-exposure Prophylaxis
Purpose: Long-acting formulations of the potent antiretroviral prodrug tenofovir alafenamide (TAF) hold potential as biomedical HIV prevention modalities. Here, we present a rigorous comparison of three animal models, C57BL/6 J mice, beagle dogs, and merino sheep for evaluating TAF implant pharmacokinetics (PKs). Methods: Implants delivering TAF over a wide range of controlled release rates were tested in vitro and in mice and dogs. Our existing PK model, supported by an intravenous (IV) dosing dog study, was adapted to analyze mechanistic aspects underlying implant TAF delivery. Results: TAF in vitro release in the 0.13 to 9.8 mg d−1 range with zero order kinetics were attained. Implants with equivalent fabrication parameters released TAF in mice and sheep at rates that were not statistically different, but were 3 times higher in dogs. When two implants were placed in the same subcutaneous pocket, a two-week creep to Cmax was observed in dogs for systemic drug and metabolite concentrations, but not in mice. Co-modeling IV and TAF implant PK data in dogs led to an apparent TAF bioavailability of 9.6 in the single implant groups (compared to the IV group), but only 1.5 when two implants were placed in the same subcutaneous pocket. Conclusions: Based on the current results, we recommend using mice and sheep, with macaques as a complementary species, for preclinical TAF implant evaluation with the caveat that our observations may be specific to the implant technology used here. Our report provides fundamental, translatable insights into multispecies TAF delivery via long-acting implants.
- 15 March 2022
- Published by Springer Nature in Nature Medicine
Russian COVID-19 vaccine in jeopardy after Ukraine invasion
- 15 March 2022
- Published by Springer Nature in Nature Medicine
Russian COVID-19 vaccine in jeopardy after Ukraine invasion
- 14 December 2021
- Published by Springer Nature in Nature Medicine
- Vol. 27 (12) , 2054-2055
COVID-19 timeline of events
- 14 December 2021
- Published by Springer Nature in Nature Medicine
- Vol. 27 (12) , 2054-2055
COVID-19 timeline of events
- 19 December 2020
- Published by American Chemical Society (ACS) in ACS Earth and Space Chemistry
- Vol. 5 (1) , 40-54
Synthesis and Characterization of Mixed-Valent Iron Layered Double Hydroxides (“Green Rust”)
- 19 December 2020
- Published by American Chemical Society (ACS) in ACS Earth and Space Chemistry
- Vol. 5 (1) , 40-54
Synthesis and Characterization of Mixed-Valent Iron Layered Double Hydroxides (“Green Rust”)